Key chiral intermediate in the synthesis of Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes. This compound features a triazolopyrazine core linked to a difluorophenyl-substituted aminobutanone moiety, enabling efficient incorporation into the final drug structure via reduction and coupling steps. It supports the development of oral antidiabetic agents that enhance incretin levels, improve glycemic control, and offer favorable pharmacokinetics with once-daily dosing.

Utilized in pharmaceutical manufacturing and research to produce high-purity Sitagliptin, contributing to therapies that minimize hypoglycemia risk and are compatible with combination regimens like metformin. Also employed in medicinal chemistry for analog synthesis to explore SAR for DPP-4 selectivity, renal safety, and metabolic stability in diabetic patients with comorbidities.